Debiopharm International, S.a.

Other

Debiopharm S.a.

Katholieke Universiteit Leuven

Debio Recherche Pharmaceutique S.a.

Grégoire Vuagniaux

Rolland-Yves Mauvernay

Linda Kadi

Jean-Maurice Dumont

Pietro Scalfaro

Roland M Wenger

Paolo Bernardi

Manfred Mutter

Patrick Garrouste

Rafael Crabbé

Olivier Turpin

Justyna Nowakowska

Laura Novaroli Zanolari

Valérie Nicolas

Robert Lysek

Anne-Mieke Vandamme

Sonia Van Dooren

Joke Snoeck

Frederick Wittke

Norbert Wiedemann

Sergio Adrian Szyldergemajn Altman

Bruno Gavillet

The present invention relates to the use of Afabicin in a method of treating bacterial infections involving biofilm that containsbacteria, wherein the method comprises administering Afabicin in combination with at least one further agent selected from lipopeptides, glycopeptides and lincosamides, such as Daptomycin and/or Vancomycin to the patient.

Medicament and use thereof for treating bacterial infections involving biofilm

The present invention provides means and methods for treating diabetic foot infections. In particular, drug compounds are provided that combine a high therapeutic activity againstSpp. bacteria with a high degree of bone penetration and vasodilatory effects. This unique combination of properties allows to accomplish high local concentrations of the drug at the site of infection even in diabetic foot patients typically having poor blood perfusion at the site of infection.

Medicament for treatment of diabetic foot infections

The invention relates to assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.

Near full-genome assay of HCV drug resistance

The invention relates to the use of a cyclic undecapeptide, with the structure in formula (I), for the preparation of a medicament for administration during a myocardial ischaemic event.

Use of a cyclic undecapeptide for the preparation of a medicament for administration during myocardial ischaemic events

At least one embodiment of the present invention relates to new cycloundecadepsipeptide compounds and to the use of said compounds as a medicament, in particular as antiviral agents, more particularly for preventing or treating Hepatitis C infections or HCV induced disorders.

Cycloundecadepsipeptide compounds and use of said compounds as a medicament

The present invention relates to the use of a nonimmunosuppressive cyclosporin A derivative for reducing mitochondrial dysfunction and the rate of apoptosis of muscle cells of patients diagnosed with Ullrich congenital muscular dystrophy or Bethlem myopathy.

Non-immunosuppressive cyclosporin for treatment of Ullrich congenital muscular dystrophy

This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.

Use of a cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said cyclosporin

Use of selected cyclosporins for the treatment of hepatitis C infection

Growing community of inventors

Lausanne, Switzerland

Grégoire Vuagniaux